18 results
8-K
EX-99.1
ONCR
Oncorus, Inc.
22 May 23
Oncorus Reports First Quarter 2023 Financial Results and Provides Business Updates
4:13pm
(Ted) Ashburn, M.D., Ph.D., President and Chief Executive Officer of Oncorus. "Our exceptional team continues to drive our mission of realizing the full
8-K
EX-99.1
ONCR
Oncorus, Inc.
30 Nov 22
Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer
7:07am
and reiterating guidance for its cash runway into early 2024.
“Oncorus’ mission is now focused on realizing the full promise of IV-administered, self-amplifying
8-K
EX-99.1
ONCR
Oncorus, Inc.
10 Jan 22
Regulation FD Disclosure
8:17am
for ONCR-GBM Cash through late 2023* Upcoming Catalysts *Certain activities in 2023 noted above are contingent upon additional financing
Mission
8-K
EX-99.1
ONCR
Oncorus, Inc.
29 Jul 21
Oncorus Expands its Board with Appointment of Barbara Yanni
4:31pm
our mission of realizing the full promise of viral immunotherapies for cancer patients,” said Theodore (Ted) Ashburn, M.D., Ph.D., President and CEO … science, pipeline diversification, a comprehensive manufacturing strategy, and a mission-driven mindset,” said Ms. Yanni. “I’m thrilled to join Oncorus
8-K
EX-99.1
ONCR
Oncorus, Inc.
10 Mar 21
Oncorus Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights
7:15am
buildout phase of our GMP clinical manufacturing facility. We look forward to continued growth throughout 2021, driven by our mission to realize the full
424B4
xcl5m20subqi3n3adnsj
12 Feb 21
Prospectus supplement with pricing info
4:23pm
DRS
qgshf07ro3psty1rv
28 Jan 21
Draft registration statement
12:00am
8-K
EX-99.1
hdk fmsyql
4 Jan 21
Entry into a Material Definitive Agreement
4:12pm
8-K
EX-99.1
jo0tf14j1zvtfzyseujy
14 Dec 20
Oncorus Appoints Scott Canute to its Board of Directors
9:03am
8-K
EX-99.1
212yjb8mkl4
12 Nov 20
Oncorus Reports Third Quarter 2020 Financial Results and Provides Business Highlights
7:00am
424B4
smykg9dw54e1 nvil
2 Oct 20
Prospectus supplement with pricing info
12:00am
S-1
a48c g2g8x9cw94kv
11 Sep 20
IPO registration
4:49pm
DRS/A
6u35r
26 Aug 20
Draft registration statement (amended)
12:00am
DRS/A
hsl6xohwego
29 Jul 20
Draft registration statement (amended)
12:00am
DRS/A
dilm1ztv
20 Dec 19
Draft registration statement (amended)
12:00am
DRS
u68klujp24dhxj0ehc
31 Oct 19
Draft registration statement
12:00am
- Prev
- 1
- Next